Overview

* Vivani reports Q3 net loss widening to $6.5 mln, with increased operating expenses

* Vivani secures $25.7 mln in cash and commitments for development projects

Outlook

* Vivani plans Phase 1 study of semaglutide implant in early 2026

* Company preparing for Phase 2 study pending Phase 1 results

* Vivani expects Cortigent spin-off post-SEC operations resumption

Result Drivers

* FUNDING SECURED - Vivani secures $25.7 mln in cash and commitments to support accelerated development of NPM-139

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.11

Q3 Net -$6.53

Income mln

Q3 -$6.73

Income mln

from

Operatio

ns

Q3 $6.73

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Vivani Medical Inc ( VANI ) is $4.00, about 61.7% above its November 12 closing price of $1.53

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)